Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.65 |
| ▸ | MAOA | P21397 | 6/20 | 0.57 |
| ▸ | MAOB | P27338 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557322 | 1.00 | CALML3 (0.65) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL2898382 | 0.87 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL2898383 | 0.87 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL1394138 | 0.87 | F10 (0.52) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1036374 | 0.87 | F10 (0.52) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10196158 | 0.87 | CALML3 (0.50) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5917588 | 0.87 | F10 (0.52) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3323285 | 0.86 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL3323279 | 0.86 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL3323276 | 0.86 | CALML3 (0.80) | CALML3MAOAMAOBCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| EP-3372596-B1 | PREPARATION METHOD FOR TEDIZOLID, TEDIZOLID INTERMEDIATE, AND PREPARATION METHOD THEREFOR | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2020-07-22 | — | — | EP | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-08-20 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| EP-1427711-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | disclosed |
| WO-2003035648-A1 | ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003022824-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003006440-A2 | AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | CYP51A1, CYP2F1, CYP4F11 | CALML3 4289/4885MAOA 1342/4885MAOB 692/4885 |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | NR4A1, NR0B1, NR1D1 | CALML3 3757/4885MAOA 3466/4885MAOB 3207/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | CALML3 3149/4885MAOA 957/4885MAOB 976/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | CALML3 2223/4885MAOA 379/4885MAOB 219/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | CALML3 3583/4885MAOA 1179/4885MAOB 732/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | CALML3 4401/4885MAOA 1569/4885MAOB 1093/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.